AI21 Labs Raises $64 Million to Change the Way People Read and Write Using Artificial Intelligence

12 July, 2022

The funding round was led by Ahren and brings AI21 Labs valuation to $664 million.

Tel Aviv, Israel – July 12, 2022AI21 Labs, an Isareli startup aiming to fundamentally change the way people read and write, announced today the completion of its $64 million series B funding round, bringing the company’s valuation to $664 million. The round was led by Ahren with participation from existing investors, including Prof’ Amnon Shashua, Walden Catalyst, Pitango, TPY Capital and Mark Leslie. The current round brings the company’s total fundraising to $118 million. The funding will be used to invest in R&D and recruit new marketing and sales employees. Ahren will become a founding member of AI21 Labs’ Advisory Board.

AI21 Labs specializes in Natural Language Processing (NLP) and has built AI21 Studio, an NLP-as-a-Service developer platform where developers can purchase state-of-the-art pre-trained and custom language models to build text-based applications, serving companies like Publicis and Latitude. AI21 Studio also features the company’s newest product, Jurassic-X, an advanced natural language processing system that can handle tasks that lie beyond the reach of neural models alone.

The company has launched several products, including Wordtune, a browser extension with millions of active users that was chosen by Google as one of its favorite extensions for 2021, as well as Wordtune Read, which analyzes and summarizes documents in seconds, enabling users to read long and complex text quickly and efficiently.

“We completed this round during a period of market uncertainty, which highlights the confidence our investors have in AI21’s vision to change the way people consume and produce information,” said Ori Goshen, co-founder and co-CEO. “The funding will allow us to accelerate the company’s global growth, while continuing to develop advanced technology in the field of natural language processing. We are looking forward to growing our team and our offerings.”

“NLP has reached a critical inflection point and AI21 has developed unique infrastructure and products to successfully serve a large and rapidly growing market” said Alice Newcombe-Ellis, Founding and General Partner of Ahren. “We consider this team to be of the highest caliber, both technically and commercially, leading a differentiated company in a transformative space”.

Since first closing in 2019, Ahren has grown its assets under management to >$800 million and its portfolio to 22 companies across stages including three which have since become unicorns, two which have gone public and one which has been acquired. Ahren recently did a large first close of its successor fund. Core to Ahren’s success is a strong partnership between its investment talent and its co-founding Science Partners, an interdisciplinary group who have previously built technologies and companies today worth over $100 billion. They include Professor Zoubin Ghahramani, VP Research at Google AI who previously founded and led Uber AI labs, amongst distinguished others.

About AI21 Labs
AI21 Labs is an artificial intelligence startup whose mission is to reimagine the way we read and write by making the machine a thought partner to humans. The company has built state of the art language models that are publicly available via AI21 Studio. Wordtune, AI21’s premier product, is the first AI-based writing companion that understands context and meaning. The company was founded in 2017 by AI pioneers Yoav Shoham, Ori Goshen, and Amnon Shashua. The company’s headquarters are in Tel Aviv, Israel. For more information, visit:

About Ahren
Ahren is a deep tech and deep science investment firm set up by Alice Newcombe-Ellis alongside co-founding Science Partners that have founded companies and/or technologies that are today valued in excess of $100BN combined. The firm was established from first principles with a mission to be disruptive as an investment institution, with a new model – genuine partnership between the creators of deep technology and deep science, and commercially active, long-term capital, to harness tremendous global talent and build and exponentially accelerate the next generation of great enterprises. Ahren’s Portfolio companies include AI21 Labs, Graphcore, Zapata Computing, ZOE, Phaidra, Heirloom Carbon, and Bicycle Therapeutics among others. Ahren has >$800M AUM and has team members in Cambridge (UK), London, and Boston. Learn more at

This press release does not constitute an offer of interests in any Ahren fund. Any offer of an Ahren fund will be made through separate offering documents and in accordance with applicable laws and regulations. This press release may contain forward looking statements. These statements include, but are not limited to, discussions related to Ahren’s expectations regarding the performance of its business, its liquidity and capital resources and the other statements contained herein. These forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. When used in this press release, the words “believe,” “anticipate,” “estimate,” “expect,” “intend” and similar expressions are intended to identify forward-looking statements. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. These statements are subject to certain risks, uncertainties and assumptions. Ahren gives no undertaking or assumes any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.
Ahren believes that selected case studies should be considered as a reflection of Ahren’s investment process, and references to these particular portfolio companies should not be considered as recommendations of any particular security, investment or portfolio company. The information provided about these portfolio companies is intended to be illustrative, and is not intended to be used as an indication of the current or future performance of the portfolio companies of the fund that Ahren manages.
prev page Ahren Leads $30mn Funding Round in Cambridge Epigenetix next page OxDX Raises £2.6M Pre-Seed Funding to Develop AI Powered Rapid Diagnostic Technology

We use cookies to give you the best experience on our website. Learn more.